NASDAQ:ITCI Intra-Cellular Therapies (ITCI) Stock Price, News & Analysis $131.87 0.00 (0.00%) As of 04/2/2025 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock About Intra-Cellular Therapies Stock (NASDAQ:ITCI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get ITCI alerts:Sign Up Key Stats Today's Range$131.87▼$131.8750-Day Range$128.20▼$131.9252-Week Range$64.09▼$131.98VolumeN/AAverage Volume1.48 million shsMarket Capitalization$14.05 billionP/E RatioN/ADividend YieldN/APrice Target$109.70Consensus RatingHold Company OverviewIntra-Cellular Therapies, Inc., a biopharmaceutical company, focuses on the discovery, clinical development, and commercialization of small molecule drugs that address medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms in the central nervous system (CNS) in the United States. The company offers CAPLYTA for the treatment of schizophrenia and bipolar depression in adults. It is also involved in developing Lumateperone, which is in Phase 3 clinical trial for the treatment of various depressive disorders, as well as additional neuropsychiatric indications. In addition, the company is developing Lenrispodun (ITI-214) for the treatment of Parkinson's disease, CNS, and other disorders; ITI-1284 for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia; and ITI-333 for substance use disorders, pain, and psychiatric comorbidities, including depression, anxiety, and sleep disorders. Intra-Cellular Therapies, Inc. was founded in 2002 and is headquartered in New York, New York.Read More… Intra-Cellular Therapies Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks17th Percentile Overall ScoreITCI MarketRank™: Intra-Cellular Therapies scored higher than 17% of companies evaluated by MarketBeat, and ranked 293rd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion1.1 / 5Analyst RatingHold Consensus RatingIntra-Cellular Therapies has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 10 hold ratings, and no sell ratings.Amount of Analyst CoverageIntra-Cellular Therapies has only been the subject of 3 research reports in the past 90 days.Read more about Intra-Cellular Therapies' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Intra-Cellular Therapies are expected to grow in the coming year, from ($0.64) to $0.19 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Intra-Cellular Therapies is -151.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIntra-Cellular Therapies has a P/B Ratio of 21.44. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Intra-Cellular Therapies' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for ITCI. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldIntra-Cellular Therapies does not currently pay a dividend.Dividend GrowthIntra-Cellular Therapies does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-1.23 Short InterestThere is no current short interest data available for ITCI. News and Social Media0.6 / 5News Sentiment0.00 News Coverage This WeekMarketBeat has tracked 2 news articles for Intra-Cellular Therapies this week, compared to 8 articles on an average week.Search Interest11 people have searched for ITCI on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Intra-Cellular Therapies to their MarketBeat watchlist in the last 30 days. This is a decrease of -92% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Intra-Cellular Therapies insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.60% of the stock of Intra-Cellular Therapies is held by insiders.Percentage Held by Institutions92.33% of the stock of Intra-Cellular Therapies is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Intra-Cellular Therapies' insider trading history. Receive ITCI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Intra-Cellular Therapies and its competitors with MarketBeat's FREE daily newsletter. Email Address ITCI Stock News HeadlinesPhathom Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business UpdateMay 1 at 7:00 AM | globenewswire.comIntra-Cellular Therapies (NASDAQ:ITCI) Now Covered by Analysts at StockNews.comApril 30, 2025 | americanbankingnews.comTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.May 4, 2025 | Porter & Company (Ad)Intra-Cellular Therapies (ITCI) Receives a Rating Update from a Top AnalystApril 3, 2025 | markets.businessinsider.com5ITCI : Demystifying Intra-Cellular Therapies: Insights From 6 Analyst...April 2, 2025 | benzinga.comIntra-Cellular TherapiesMarch 29, 2025 | forbes.comIntra-Cellular Therapies announces proxy statement supplementMarch 20, 2025 | uk.investing.comIntra-Cellular Therapies Stock Hits All-Time High of $131.47March 18, 2025 | investing.comSee More Headlines ITCI Stock Analysis - Frequently Asked Questions How have ITCI shares performed this year? Intra-Cellular Therapies' stock was trading at $83.52 at the beginning of 2025. Since then, ITCI shares have increased by 57.9% and is now trading at $131.87. View the best growth stocks for 2025 here. How were Intra-Cellular Therapies' earnings last quarter? Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) announced its quarterly earnings results on Friday, February, 21st. The biopharmaceutical company reported ($0.16) earnings per share for the quarter, missing the consensus estimate of ($0.08) by $0.08. The biopharmaceutical company earned $199.22 million during the quarter, compared to analysts' expectations of $205.08 million. Intra-Cellular Therapies had a negative net margin of 14.07% and a negative trailing twelve-month return on equity of 9.93%. Who are Intra-Cellular Therapies' major shareholders? Intra-Cellular Therapies' top institutional shareholders include CIBRA Capital Ltd (0.39%), Bank of New York Mellon Corp (0.33%), Syquant Capital Sas (0.25%) and Rhumbline Advisers (0.12%). Insiders that own company stock include Sharon Mates, Rory B Riggs, Joel S Marcus, Mark Neumann, Suresh K Durgam, Nostrand Robert L Van, Lawrence J Hineline and Michael Halstead. View institutional ownership trends. How do I buy shares of Intra-Cellular Therapies? Shares of ITCI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Intra-Cellular Therapies own? Based on aggregate information from My MarketBeat watchlists, some other companies that Intra-Cellular Therapies investors own include Humana (HUM), American Water Works (AWK), Voyager Therapeutics (VYGR), Waste Connections (WCN), The RMR Group (RMR), DiamondRock Hospitality (DRH) and Southern First Bancshares (SFST). Company Calendar Last Earnings2/21/2025Today5/03/2025Next Earnings (Estimated)5/06/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ITCI CIK1567514 Webwww.intracellulartherapies.com Phone(464) 440-9333Fax646-440-9334Employees560Year FoundedN/APrice Target and Rating Average Stock Price Target$109.70 High Stock Price Target$132.00 Low Stock Price Target$74.00 Potential Upside/Downside-16.8%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage12 Analysts Profitability EPS (Most Recent Fiscal Year)($0.73) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-139,670,000.00 Net Margins-14.07% Pretax Margin-13.87% Return on Equity-9.93% Return on Assets-8.38% Debt Debt-to-Equity RatioN/A Current Ratio7.66 Quick Ratio7.51 Sales & Book Value Annual Sales$680.50 million Price / Sales20.64 Cash FlowN/A Price / Cash FlowN/A Book Value$6.15 per share Price / Book21.44Miscellaneous Outstanding Shares106,522,000Free Float103,563,000Market Cap$14.05 billion OptionableOptionable Beta0.69 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report This page (NASDAQ:ITCI) was last updated on 5/4/2025 by MarketBeat.com Staff From Our PartnersThink NVDA’s run was epic? You ain’t seen nothin’ yetAsk most investors and they’ll probably tell you Nvidia is the undisputed AI stock of the decade. In 2023, ...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Robots aren't coming to America in 2025. They are already here. Oxford Economics says, "The Robotics Rev...Weiss Ratings | SponsoredWill May start the next "Great Depression?"You probably haven't heard about this yet... But this could be the biggest wealth building opportunity of t...Behind the Markets | SponsoredDOGE officially begins retirement transformationElon Musk's Department of Government Efficiency ("DOGE") just announced the first-ever "fully digital retireme...Altimetry | SponsoredWhy Elon put $51 million into thisWhile fear dominates the headlines, a silent breakthrough could turn panic into profit. The future of AI fa...True Market Insiders | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Intra-Cellular Therapies, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Intra-Cellular Therapies With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.